Child looking through binoculars

Spotting the Early Signs of Pancreatic Cancer

Pancreatic cancer is usually diagnosed at a late stage, which has resulted in the disease having particularly poor survival rates around the world. Finding methods to allow earlier detection and treatment could massively improve patient survival, and are a hot research topic in the field. A recent study investigating altered metabolism in pancreatic adenocarcinoma patients… Read more »

black targets and arrow sky

Leukemia: A New Target for PARP Inhibitors?

Many agents in cancer research target specific molecules or pathways, meaning they are only effective in a certain subset of patients. Finding another use for an already developed drug can cut down on early stage research and offer new hope to other patient groups. This could be happening soon in leukemia, where preclinical research has… Read more »

england hand resize2

Oncology Agents Not Having a NICE Time in England

Potential new oncology agents in England need to be approved by the National Institute for Health and Care Excellence (NICE) based on their cost-effectiveness. However over the past couple of years and much to the disappointment of the general public, NICE have rejected a string of oncology agents, including recently Kadcyla® for advanced breast cancer…. Read more »

mic narrow

Essential ESMO: Crizotinib Takes Center Stage

Last week saw the close of the 2014 European Society for Medical Oncology congress in Madrid, the theme of which was ‘Precision Medicine in Cancer Care’. Crown Bioscience have reviewed the best of the research to be presented, and were particularly interested to see crizotinib back in the spotlight in a potential new NSCLC indication.